This site is intended for healthcare professionals only.

Integrating Ketone and Glucose Monitoring for Optimized Diabetes Management

Are you up to date with the latest advancements in ketone monitoring?

Diabetic ketoacidosis (DKA) remains a serious and potentially life-threatening complication of diabetes mellitus, primarily affecting individuals with type 1 diabetes (T1D) but increasingly observed in those with type 2 diabetes (T2D). The integration of diabetes technology, including continuous ketone monitoring (CKM), presents challenges for both patients and clinicians.

CME available

1.0 AMA PRA Category 1 Credits™ available (look for the badge)

Interested in learning more? Listen to Dr. David Kerr as he discusses the goals of this CME Program.

Learning Objectives

Following completion of this independent educational program, you will be able to: 


  • Identify the most recent guidelines and definitions of DKA.
  • Explain the etiology and identify risk factors of DKA.
  • Evaluate current and emerging ketone monitors, including CKMs, and their recent clinical trial data.
  • Describe the most useful clinical scenarios to use various ketone monitoring systems.
  • Identify patient barriers preventing optimal ketone monitoring.

About the Program

Our CME-accredited Ketone Monitoring Masterclass, an on-demand digital learning experience, will update you on guidelines, pathophysiology of DKA, innovations in ketone monitoring, and overcoming barriers to ketone monitoring.

Target Audience

This program is aimed at US-based primary care physicians (PCPs) who are looking to improve their knowledge and skills in ketone monitoring technology for patients with T2D.

Program Activities

Experience on-demand, digital e-learning modules that examine the landscape of ketone monitoring. 

Hourglass © MARHARYTA MARKO/Getty Images/iStock

Listen to the program director highlight and dive into breaking news and clinical implications of data presented at the 2025 American Diabetes Association (ADA) conference. 

Learning Objectives

Following completion of this independent educational program, you will be able to: 


  • Identify the most recent guidelines and definitions of DKA.
  • Explain the etiology and identify risk factors of DKA.
  • Evaluate current and emerging ketone monitors, including CKMs, and their recent clinical trial data.
  • Describe the most useful clinical scenarios to use various ketone monitoring systems.
  • Identify patient barriers preventing optimal ketone monitoring.

About the Program

Our CME-accredited Ketone Monitoring Masterclass, an on-demand digital learning experience, will update you on guidelines, pathophysiology of DKA, innovations in ketone monitoring, and overcoming barriers to ketone monitoring.

Target Audience

This program is aimed at US-based primary care physicians (PCPs) who are looking to improve their knowledge and skills in ketone monitoring technology for patients with T2D.

Meet the Faculty

Program Director

Center for Health Systems Research, Sutter Health 
Santa Barbara, CA 
United States

Faculty Member

Professor of pediatrics
CT, United States

Faculty Member

University of California San Francisco (UCSF)
San Francisco, CA 
United States

Accreditation

In support of improving patient care, this program has been planned and implemented by the Postgraduate Institute for Medicine and Springer Healthcare IME. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the program.

Planning Committee

In addition to the expert faculty, the Postgraduate Institute for Medicine and Springer Healthcare IME planners and staff include Holly Keatts, Judith Mitchek, Maria Glukhovsky, Elizabeth Samander, Alessandra Geffner-Smith, and Kristen Rogers. The Planning Committee has no financial relationships to disclose. 

All relevant financial relationships of the faculty have been mitigated. 

David Kerr

Program Director

David Kerr, MBChB, DM, FRCP, FRCPE

Center for Health Systems Research, Sutter Health 
Santa Barbara, CA 
United States

Dr. David Kerr, MBChB, DM, FRCP, FRCPE, a UK trained endocrinologist is currently Senior Investigator in Diabetes and Digital health Equity at the Sutter Health Center for Health Systems Research in Santa Barbara, California (https://www.davidkerrmd.com/).

Dr. Kerr’s recent research has focused on offering wearable digital health technologies, such as continuous glucose monitoring (CGM) devices, to marginalized and historically excluded communities to help them understand the potential value of real-time physiologic data. He has published more than 400 articles, commentaries, and opinion pieces, as well as co-authored the first three books focusing on diabetes and digital health. Dr. Kerr has a Google Scholar i10-index of 173 and an h-index of 54.

Dr. Kerr’s research has also included the use of “food as medicine” for adults with or at-risk of diabetes. He has published the outcomes showing measurable clinical and mental health benefits from the prescription of fresh vegetable produce. Dr. Kerr also has an adjunct position in the department of Computer Science and Electrical Engineering at Rice University in Houston, Texas, is a member of the research committee of the Association of Diabetes Care and Education Specialists, and was recently co-chair of an National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) working group that looked at the impact of innovation on furthering research into the heterogeneity of diabetes.

You can follow Dr. Kerr on “X” at @godiabetesmd

Disclosures:  

  • Grant/research support: Abbott Diabetes Care 
Jennifer L. Sherr

Faculty Member

Jennifer L. Sherr, MD, PhD

Professor of pediatrics
CT, United States

Dr. Jennifer L. Sherr was determined to become a pediatric endocrinologist since the time of her diagnosis with T1D in 1987. While she always wanted to care for those with T1D, her eyes were opened to the meaningful impact that clinical research has. Dr. Sherr has been devoted to clinical research for more than 15 years. She serves as the Medical Director of Pediatric Diabetes and Professor in the Department of Pediatrics at Yale and focuses on methods to improve the lives of all people living with diabetes, including new technologies and therapeutics. 

Disclosures:  

  • Grant/research support: Abbott Diabetes, Dexcom, Insulet, JDRF/Breakthrough T1D, Medtronic, NIG, Provention Bio 
  • Consultant/advisory board: Abbott Diabetes, Cecelia Health, Insulet, Mannkind, Medscape, Medtronic Diabetes, StartUp Health T1D Moonshot, Vertex, Ypsomed 

*Dr. Sherr’s contribution to this publication was made in their individual capacity and not as part of their Yale University duties or responsibilities

Eda Cengiz

Faculty Member

Eda Cengiz, MD

University of California San Francisco (UCSF)
San Francisco, CA
United States

Dr. Eda Cengiz is a professor of pediatrics, pediatric diabetologist by training at the University of California San Francisco (UCSF) School of Medicine, Benioff UCSF professor in children’s health. She is the cross-bay director of the UCSF pediatric diabetes program.

Dr. Cengiz is a pediatric endocrinologist by training, and her research focuses on diabetes technology and insulin action. She has had a chance to work and publish with experts in the filed regarding substance abuse on diabetes management to improve outcomes for people with diabetes who are navigating the complexities of diabetes. 

Disclosures:  

  • Employee/owner: UCSF
  • Grant/research support: Breakthrough T1D, Helmsley, NIH
  • Speakers bureau/honoraria for non-CME: Novo Nordisk
  • Consultant/advisory board: Adocia, Arecor, Eli Lilly, MannKind, Novo Nordisk, Portal Insulin, Tandem, Ypsomed